• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Follow-up Colonoscopy: When Should This Patient Return?

Poll

Is a surveillance interval of 1 year, 3 years, 5, or 10 years recommended?

A 50-year-old man of average risk undergoes a first-time screening colonoscopy. A sub-centimeter polyp was found in the ascending colon and was removed. Histology revealed a sessile serrated adenoma.  

When should a repeat colonoscopy be performed?

A. 1 year
B. 3 years
C. 5 years
D. 10 years
Related Videos
Related Content
Rideshare Support for Post-FIT Colonoscopy May Cut CRC Deaths and Save Costs: Daily Dose / Image credit: ©New Africa/AdobeStock

Rideshare Support for Post-FIT Colonoscopy May Cut CRC Deaths and Save Costs: Daily Dose

Sydney Jennings
October 15th 2025
Article

Your daily dose of the clinical news you may have missed.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Sydney Jennings
August 28th 2025
Podcast

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose / image credit: ©New Africa/AdobeStock

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose

Sydney Jennings
October 14th 2025
Article

Your daily dose of the clinical news you may have missed.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

FDA Approves Guselkumab as First IL-23 Inhibitor With Fully Subcutaneous Regimen for Ulcerative Colitis / Image credit: ©muhammed/AdobeStock

FDA Approves Guselkumab as First IL-23 Inhibitor With Fully Subcutaneous Induction Regimen for Ulcerative Colitis

Sydney Jennings
September 22nd 2025
Article

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.

Rideshare Program Could Improve Colonoscopy Completion and Reduce CRC Burden, Study Finds

Rideshare Program Could Improve Colonoscopy Completion and Reduce CRC Burden, Study Finds

Sydney Jennings
September 12th 2025
Article

A new modeling study suggests rideshare programs could double colonoscopy completion after abnormal FIT results, cutting colorectal cancer incidence and deaths while saving health care costs.

© 2025 MJH Life Sciences

All rights reserved.